We believe that NCTD is an effective “more targets” anticancer agent for human gallbladder cancers by “multifactor” and “multi-points priming” mechanisms [51]; that inhibition of gallbladder cancer VM by NCTD via blocking the EphA2/FAK/Paxillin pathway may be one of “more targets” anticancer mechanisms of NCTD. The gene discussed is EPHA2; the disease is gallbladder cancer.